Contineum Therapeutics Inc. (CTNM) stock
Price, quality score, analyst targets, a 30-day Kronos AI forecast and a Shariah screen for Contineum Therapeutics Inc., updated every trading day.
Health Care · Biotechnology: Pharmaceutical Preparations
Price
$9.15
+1.78% today
Market cap
$338M
Overall quality
45/100
Kronos AI 30-day
+49.7%
8 of 8 simulated paths end higher
Contineum Therapeutics Inc. (CTNM) is a Health Care company in Biotechnology: Pharmaceutical Preparations, worth $338M. It trades at $9.15, up 1.78% today. Its overall quality score is 45 out of 100, ranked against the whole US market. 7 analysts' average target of $22.14 implies +142.0% from today's price. Kronos AI's 30-day forecast is +49.7% (8 of 8 simulated paths end higher).
Open the full interactive analysis →Charts, technical signals, DCF fair value and ownership
Analyst price targets
| Average target | $22.14 |
| Low – high | $14.00 – $30.00 |
| Analysts | 7 |
| Upside to average | +142.0% |
Kronos AI 30-day forecast
| Expected close | $13.46 (+49.7%) |
| Likely range | +41.9% … +72.1% |
| As of | 2026-10-27 |
8 of 8 simulated paths end higher.
Quality scores
| Profitability | 42 |
| Solvency | 60 |
| Growth | 33 |
| Overall | 45 |
| P/E | — |
Shariah screen
| Business activity | Passes |
| Debt and cash (AAOIFI 30%) | Not checked for this listing |
Automated screen of business activity and AAOIFI's 30% debt and cash limits. The 5% impermissible-income test is not applied. Check with a scholar before deciding.
Similar companies in Biotechnology: Pharmaceutical Preparations
For information only, not investment advice. Prices updated: 2026-10-29.